Equities

Quince Therapeutics Inc

QNCX:NSQ

Quince Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8653
  • Today's Change0.105 / 13.86%
  • Shares traded309.51k
  • 1 Year change-28.49%
  • Beta0.8480
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7590107
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.302.293.38
Other current assets, total0.081.281.50
Total current assets7794112
Property, plant & equipment, net0.620.681.43
Goodwill, net18----
Intangibles, net645.90--
Long term investments0.083.5820
Note receivable - long term------
Other long term assets8.4600.19
Total assets168104133
LIABILITIES
Accounts payable2.030.574.91
Accrued expenses3.442.429.31
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.08--
Other current liabilities, total4.10----
Total current liabilities9.573.0714
Total long term debt1300
Total debt130.080
Deferred income tax5.300.25--
Minority interest------
Other liabilities, total5500.42
Total liabilities833.3215
SHAREHOLDERS EQUITY
Common stock0.040.040.03
Additional paid-in capital402389355
Retained earnings (accumulated deficit)(320)(288)(237)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total3.05(0.29)(0.08)
Total equity85101119
Total liabilities & shareholders' equity168104133
Total common shares outstanding433630
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.